No Data
Yunnan Jianzhijia Health-Chain (605266.SH) spent 94.9581 million yuan to complete the buyback of 2.77% of its shares.
Yunnan Jianzhijia Health-Chain (605266.SH) announced that the share repurchase will expire on January 29, 2025, ...
2024 Annual Results Pre-Reduction Announcement
Yunnan Jianzhijia Health-Chain (605266.SH): The net profit for 2024 is expected to decrease by 68.78% to 65.50%.
On January 17th, Gelonghui announced that Yunnan Jianzhijia Health-Chain (605266.SH) has projected a reduction in its annual performance announcement for 2024. The net income attributable to shareholders of the listed company is expected to decrease by 285.0476 million yuan to 271.4304 million yuan compared to the same period last year, a year-on-year decrease of 68.78% to 65.50%. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses is expected to decrease by 276.179 million yuan to 263.1212 million yuan compared to 399.373 million yuan in the same period last year.
Not Many Are Piling Into Jianzhijia Pharmaceutical Chain Group Co., Ltd. (SHSE:605266) Stock Yet As It Plummets 25%
Yunnan Jianzhijia Health-Chain (605266.SH): A total of 0.58% of shares have been repurchased, and the repurchase period has expired.
According to the announcement on December 19 by Gelonghui, Yunnan Jianzhijia Health-Chain (605266.SH) reported that as of the date of the announcement, the share repurchase period has expired. The company has repurchased a total of 0.9034 million shares through the Shanghai Exchange via centralized bidding, accounting for 0.58% of the company’s total shares. The repurchase price ranged from 18.21 to 27.31 yuan per share, with a total amount of funds used reaching 20.4969 million yuan, which has met the lower limit of the repurchase amount for the scheme. The progress of the repurchased shares complies with relevant laws and regulations as well as the requirements of the company's share repurchase plan.
A Note On Jianzhijia Pharmaceutical Chain Group Co., Ltd.'s (SHSE:605266) ROE and Debt To Equity
Jianzhijia Pharmaceutical Chain Group Co., Ltd. (SHSE:605266) Looks Inexpensive But Perhaps Not Attractive Enough
